Mallinckrodt (MNK) Hits New Lifetime High Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Mallinckrodt ( MNK) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Mallinckrodt as such a stock due to the following factors:

  • MNK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $151.6 million.
  • MNK has traded 252,365 shares today.
  • MNK is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MNK with the Ticky from Trade-Ideas. See the FREE profile for MNK NOW at Trade-Ideas

More details on MNK:

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API), and diagnostic imaging agents worldwide. MNK has a PE ratio of 79.7. Currently there are 8 analysts that rate Mallinckrodt a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Mallinckrodt has been 2.8 million shares per day over the past 30 days. Mallinckrodt has a market cap of $5.2 billion and is part of the health care sector and drugs industry. Shares are up 72.2% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates Mallinckrodt as a sell. Among the areas we feel are negative, one of the most important has been very high debt management risk by most measures.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

The Stock Market Gets Smashed -- Here Are Some Terrible Performers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Earnings Are Back With a Vengeance: Cramer's 'Mad Money' Recap (Monday 7/24/17)